Diary - News
All news Biom’up has trained 200 surgeons in the US and in Europe ahead of HEMOBLAST Bellows™ launch
New York (N.Y.)/Saint-Priest, France, April 24, 2018 – Biom'up (EPA: BUP), a specialist in surgical hemostasis, today announced that its intensive training program to train surgeons in the use of its lead product HEMOBLAST Bellows is on track and has reached the Company’s objective of 200 trained surgeons ahead of the launch of HEMOBLAST Bellows in mid-2018 in the US and in Europe.
To prepare the surgical community for the imminent launch of HEMOBLAST Bellows, Biom’up ran 6 highly attended training sessions for surgeons in the U.S. and Europe, which were led by the Company’s experts in collaboration with key opinion leaders in surgical hemostasis. The HEMOBLAST Bellows boot camps will continue in the months ahead with more surgeons to be fully trained on HEMOBLAST Bellows.
Etienne Binant, Chief Executive Officer, said: “We are extremely encouraged by the positive feedback collected after our boot camps regarding the efficacy and ease of use of HEMOBLAST Bellows. It confirms the findings of market research conducted in early 2017, which concluded that 93% of surgeons who tried HEMOBLAST Bellows were satisfied and would recommend its use. We will continue to run these boot camps across the U.S. and Europe to help drive adoption, and sustained use of the product, and forge strong relationships with the surgical community.”
